Helus Pivots HLP004 to GAD Monotherapy; APPROACH Phase 3 Data Still Due Q4 2026
HELP has more than doubled off its 52-week low of $3.76.
Summary
Helus Pharma used its October 21 investor presentation to recast HLP004 as a GAD monotherapy with a ~144-patient Phase 2 starting Q1 2027, while reconfirming HLP003 APPROACH Phase 3 topline data for Q4 2026.
Key Events · Product Development and Regulatory · HELP
-
HLP004 Shifted to GAD Monotherapy
Helus disclosed HLP004 is now being developed as a monotherapy for generalized anxiety disorder, changing from the previously disclosed adjunctive-therapy strategy.
-
Phase 2 GAD Study Design Detailed
The upcoming study will randomize approximately 144 adults 1:1 to 30 mg HLP004 or placebo, with change from baseline in HAM-A at Week 6 as the primary endpoint and Week 12 as the key secondary; initiation is expected in Q1 2027.
-
APPROACH Phase 3 Readout Reconfirmed
Topline data from the APPROACH Phase 3 study of HLP003 in adjunctive MDD remains on track for Q4 2026, with enrollment of 223 participants completed in July 2026 and EMBRACE enrollment continuing.
-
NDA Targeted for 2028
Helus expects to file a New Drug Application for HLP003 with the FDA in 2028, leveraging its Breakthrough Therapy Designation for a potentially expedited review pathway.
Analysis · HELP · Life Sciences
The headline item is a strategy change: HLP004 is now being developed as a monotherapy for generalized anxiety disorder rather than as an adjunctive therapy, and the company laid out the Phase 2 design — roughly 144 patients, 1:1 randomized to 30 mg or placebo, with HAM-A change at Week 6 as the primary endpoint and Week 12 as key secondary, starting in Q1 2027. That matters because it resets how investors should value the second program and widens the addressable label if it works. The near-term driver is unchanged and reconfirmed: topline APPROACH Phase 3 data for HLP003 in adjunctive MDD is still expected in Q4 2026, with an NDA targeted for 2028 under Breakthrough Therapy Designation. No financial terms, cash figures, or financing were disclosed here, so this is a pipeline and timeline update rather than a balance-sheet event.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $10.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $15.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.